Home » Stocks » Pfizer

Pfizer Inc. (PFE)

Stock Price: $34.51 USD 0.77 (2.28%)
Updated Jul 2, 2020 4:03 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 191.70B
Revenue (ttm) 50.66B
Net Income (ttm) 15.79B
Shares Out 5.55B
EPS (ttm) 2.80
PE Ratio 12.33
Forward PE 11.75
Dividend $1.52
Dividend Yield 4.40%

Stock Quote

Trading Day Jul 2, 2020
Last Price $34.51
Previous Close $33.74
Change ($) 0.77
Change (%) 2.28%
Day's Open 34.51
Day's Range 34.04 - 34.85
Day's Volume 42,951,533
52-Week Range 27.88 - 44.56

More Stats

Market Cap 191.70B
Enterprise Value 233.64B
Earnings Date (est) Jul 28, 2020
Ex-Dividend Date May 7, 2020
Shares Outstanding 5.55B
Float 5.55B
EPS (basic) 2.84
EPS (diluted) 2.80
FCF / Share 2.08
Dividend $1.52
Dividend Yield 4.40%
Earnings Yield 8.11%
FCF Yield 6.03%
Payout Ratio 51.40%
Shares Short 52.04M
Short Ratio 2.27
Short % of Float 0.94%
Beta 0.70
PE Ratio 12.33
Forward PE 11.75
P/FCF Ratio 16.59
PS Ratio 3.78
PB Ratio 2.84
Revenue 50.66B
Operating Income 9.15B
Net Income 15.79B
Free Cash Flow 11.55B
Net Cash -41.94B
Net Cash / Share -7.55
Gross Margin 82.39%
Operating Margin 18.06%
Profit Margin 31.20%
FCF Margin 22.80%
ROA 5.78%
ROE 25.41%
ROIC 20.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (16)

Buy 7
Overweight 1
Hold 8
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$40.00*
(15.91% upside)
Low
35.0
Current: 34.51
High
53.0
Target: 40.00
*Average 12-month price target from 13 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue51,75053,64752,54652,82448,85149,60551,58454,65761,03565,165
Revenue Growth-3.54%2.1%-0.53%8.13%-1.52%-3.84%-5.62%-10.45%-6.34%-
Gross Profit41,53142,39941,31840,50239,20340,02841,99844,83648,53550,377
Operating Income9,59611,88512,3068,3518,96412,24015,71611,24211,4819,471
Net Income16,27311,15321,3087,2156,9609,13522,00314,57010,0098,257
Shares Outstanding5,5695,8725,9706,0896,1766,3466,8137,4427,8178,036
Earnings Per Share2.871.873.521.171.111.423.191.941.271.02
EPS Growth53.48%-46.88%200.85%5.41%-21.83%-55.49%64.43%52.76%24.51%-
Dividend Per Share1.441.361.281.201.121.040.960.880.800.72
Dividend Growth5.88%6.25%6.67%7.14%7.69%8.33%9.09%10%11.11%-
Operating Cash Flow12,58815,82716,80216,19214,68817,08417,68416,74620,24011,454
Capital Expenditures-2,594-2,196-2,217-1,999-1,496-1,583-1,465-1,419-1,882-1,513
Free Cash Flow9,99413,63114,58514,19313,19215,50116,21915,32718,3589,941
Cash & Equivalents9,83018,83319,99217,85023,29036,12232,40832,39926,45228,479
Total Debt52,15041,74043,49142,08638,89936,68236,48937,46038,94244,013
Net Cash / Debt-42,320-22,907-23,499-24,236-15,609-560-4,081-5,061-12,490-15,534
Assets167,489159,422171,797171,615167,381167,566172,101185,798188,002195,014
Liabilities104,04295,664100,141111,776102,38495,94495,481104,120105,381106,749
Book Value63,14363,40771,30859,54464,72071,30176,30781,26082,19087,813
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pfizer Inc.
Country United States
Employees 88,300
CEO Albert Bourla

Stock Information

Ticker Symbol PFE
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: PFE

Description

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreement with Merck KGaA; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and collaboration with Valneva SE to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.